---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-014298"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:37:41.683376+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BiomX deconsolidates Israel subsidiary after insolvency proceedings

## Summary
- BiomX Ltd. (wholly owned subsidiary) filed for insolvency in Israel on Jan 25, 2026; trustee appointed.
- CEO Jonathan Solomon and CFO Marina Wolfson terminated as officers of BiomX Ltd. retroactive to Jan 25 (remain at parent).
- Company deconsolidated BiomX Ltd. effective Feb 4, 2026, deemed a significant disposition of assets.
- Pro forma shows cash of $5.4M, accumulated deficit of $205.6M; net loss for 9M 2025 reduced from $22.9M to $5.9M.
- Severance payments: 9 months for CEO, 6 months for CFO and CDO.

## SEC filing metadata
- accession: 0001213900-26-014298
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390026014298/0001213900-26-014298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390026014298/ea0276425-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-014298
- JSON: https://secwatch.observer/filing/0001213900-26-014298.json
- Plain text: https://secwatch.observer/filing/0001213900-26-014298.txt

## Source-grounded claims
- claim_id: 50f991908c738be9e69af5bda47e462e4a3eeccb
  claim: BiomX Inc. completed a disposition involving Trustee (closed 2026-02-04).
  evidence_excerpt: On February 4, 2026, the Trustee notified BiomX Ltd.’s Chief Executive Officer and Chief Financial Officer that their roles as officers of BiomX Ltd. had been terminated. The Company determined that the termination is considered as a change of control as of February 4, 2026, and that BiomX Ltd. should be deconsolidated from the Company’s consolidated financial statements. The deconsolidation of BiomX Ltd. is considered a disposition of a significant amount of assets under Item 2.01 of Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390026014298/0001213900-26-014298-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.